José Luis Revuelta-Herrero

11PUBLICATIONS
16CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Inter-organisational, extra-organisational and global information systemsChemotherapyToxicology (incl. clinical toxicology)Allergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 14, 2026
The variant c.2766+3A>T in DPYD leads to exon 21 skipping and is associated with DPD deficiency and severe fluoropyrimidine toxicity.

|Aug 06, 2026
Use of Information and Communication Technologies in Patients With Cancer Receiving Antineoplastic or Supportive Therapy: Comparative Cross-Sectional Survey.

|Jan 19, 2026
Economic impact of lung cancer clinical trials: Assessing cost savings in medication and testing.

Carolina Pizarro-Gómez, Roberto Collado-Borrell, Vicente Escudero-Vilaplana

|Sep 30, 2025
Budget impact analysis of new drugs in oncology and haematology: Principles and practice.

Javier Soto-Alsar, José L Revuelta-Herrero, Cristina Villanueva-Bueno

|Jan 17, 2022
Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients.

Juan Vicente-Valor, Vicente Escudero-Vilaplana, Roberto Collado-Borrell

|Aug 27, 2021
DPYD Exome, mRNA Expression and Uracil Levels in Early Severe Toxicity to Fluoropyrimidines: An Extreme Phenotype Approach.

Priscila Villalvazo, Belén Marzal-Alfaro, Pilar García-Alfonso

Pageof 2

Frequent Collaborators

4 joint publications

Vicente Escudero-Vilaplana

3 joint publications

Roberto Collado-Borrell

2 joint publications

Andrés Muñoz-Martín

2 joint publications

Pilar García-Alfonso